Tumor-Infiltrating Lymphocyte (TIL) Therapy: Advancing Personalized Cancer Immunotherapy Beyond CAR-T Cells

 

Introduction:
The Rise of Tumor-Infiltrating Lymphocyte (TIL) Therapy in Modern Oncology

Cancer immunotherapy has transformed the landscape of modern oncology by harnessing the body's immune system to recognize and eliminate cancer cells. Over the past decade, revolutionary treatments such as immune checkpoint inhibitors and Chimeric Antigen Receptor T-cell (CAR-T) therapy have significantly improved outcomes for patients with several hematological malignancies. However, despite these remarkable advances, many patients with solid tumors continue to experience limited treatment responses, disease recurrence, or therapy resistance. These challenges have driven researchers to explore more personalized and effective cellular immunotherapies capable of overcoming the complex biology of solid tumors.

One of the most promising breakthroughs in this field is Tumor-Infiltrating Lymphocyte (TIL) Therapy, an advanced form of adoptive cell therapy that utilizes a patient's own immune cells to fight cancer. Unlike CAR-T cell therapy, which genetically engineers T cells to recognize specific cancer antigens, TIL therapy isolates naturally occurring tumor-fighting lymphocytes directly from a patient's tumor, expands them into billions of highly active immune cells in the laboratory, and reinfuses them back into the patient to enhance the body's natural anti-tumor immune response.

The growing interest in TIL therapy has accelerated following encouraging clinical trial results in advanced melanoma and other solid tumors, as well as recent regulatory approvals that have highlighted its potential as a next-generation personalized cancer immunotherapy. Researchers are now investigating its applications across multiple cancer types, including cervical cancer, non-small cell lung cancer, ovarian cancer, head and neck cancers, and gastrointestinal malignancies. By targeting the unique immune environment of each patient's tumor, TIL therapy represents a major step toward truly individualized cancer treatment.

The integration of precision oncology, genomic profiling, biomarker discovery, artificial intelligence, and advanced cell manufacturing technologies is further enhancing the development of TIL therapy. These innovations are helping clinicians identify suitable patients, optimize immune cell expansion, improve therapeutic effectiveness, and develop combination strategies with immune checkpoint inhibitors and other targeted therapies.

In this comprehensive article, we explore the science behind Tumor-Infiltrating Lymphocyte (TIL) Therapy, its mechanism of action, clinical applications, advantages, current challenges, recent breakthroughs, and future role in advancing personalized cancer immunotherapy beyond CAR-T cell therapy.

Understanding Tumor-Infiltrating Lymphocyte (TIL) Therapy: How It Works

Tumor-Infiltrating Lymphocyte (TIL) Therapy is an advanced form of adoptive cell therapy (ACT) that harnesses a patient's own immune system to recognize and destroy cancer cells. Unlike conventional cancer treatments that directly target tumors using chemotherapy or radiation, TIL therapy strengthens the body's natural immune response by utilizing specialized T cells that have already infiltrated the tumor. These naturally occurring lymphocytes have demonstrated the ability to recognize cancer-specific antigens, making them valuable tools for personalized cancer immunotherapy.

The concept of TIL therapy emerged from the observation that certain immune cells naturally migrate into tumors in an attempt to eliminate cancer cells. However, the tumor microenvironment often suppresses these lymphocytes, preventing them from mounting an effective immune response. Scientists discovered that by isolating these tumor-reactive T cells, expanding them outside the body under controlled laboratory conditions, and reinfusing billions of activated lymphocytes back into the patient, they could significantly enhance anti-tumor immunity.

Today, TIL therapy is considered one of the most promising treatments for advanced solid tumors, particularly metastatic melanoma, and is being actively investigated for several other cancers, including cervical, lung, ovarian, colorectal, and head and neck cancers.

 

How Tumor-Infiltrating Lymphocyte (TIL) Therapy Works

The treatment process involves several carefully coordinated steps designed to maximize the number and activity of tumor-fighting immune cells.

Step 1: Tumor Tissue Collection

The first step involves surgically removing a small sample of the patient's tumor.

This tissue contains naturally occurring Tumor-Infiltrating Lymphocytes (TILs) that have already recognized cancer cells and migrated into the tumor.

Unlike CAR-T therapy, which requires collecting immune cells from peripheral blood, TIL therapy begins directly with the tumor itself.

 

Step 2: Isolation of Tumor-Reactive T Cells

Inside specialized laboratories, researchers carefully isolate TILs from the tumor tissue.

Only the immune cells capable of recognizing tumor antigens are selected for further expansion.

These naturally occurring T cells possess unique receptors that can identify cancer-specific proteins without requiring genetic modification.

 

Step 3: Large-Scale Expansion in the Laboratory

The isolated TILs are cultured in the laboratory using Interleukin-2 (IL-2) and other specialized growth conditions.

Over approximately two to three weeks, these immune cells multiply from a few thousand cells into billions of highly active tumor-fighting lymphocytes.

This large-scale expansion creates enough immune cells to mount a powerful anti-cancer response after reinfusion.

 

Step 4: Patient Preparation

Before receiving the expanded TILs, patients typically undergo lymphodepleting chemotherapy.

This temporary reduction of existing immune cells creates space for the newly expanded TILs and removes immune cells that might suppress their activity.

As a result, the transferred lymphocytes can survive longer and function more effectively.

 

Step 5: TIL Infusion

The expanded TILs are infused back into the patient's bloodstream through intravenous administration.

These activated immune cells circulate throughout the body, migrate toward tumor sites, and recognize cancer cells carrying their target antigens.

Once they encounter tumor cells, they release cytotoxic molecules that destroy malignant cells while sparing most healthy tissues.

 

Step 6: Immune System Activation

Following infusion, patients often receive high-dose Interleukin-2 (IL-2) to support the growth, survival, and long-term persistence of the transferred lymphocytes.

The activated TILs continue attacking cancer cells while stimulating broader immune responses against the tumor.

This process helps establish durable anti-tumor immunity that may continue long after treatment.

 

How TIL Therapy Differs from CAR-T Cell Therapy

Although both TIL therapy and CAR-T cell therapy belong to the family of adoptive cell therapies, they differ significantly in their approach.

Tumor-Infiltrating Lymphocyte (TIL) Therapy	CAR-T Cell Therapy
Uses naturally occurring tumor-reactive T cells	Uses genetically engineered T cells
Cells are collected directly from the tumor	Cells are collected from peripheral blood
No genetic modification required	Requires laboratory genetic engineering
Particularly effective for solid tumors	Most successful in blood cancers
Recognizes multiple tumor antigens naturally	Targets one or a few specific antigens
Personalized using each patient's tumor	Personalized using engineered receptors

These differences make TIL therapy particularly attractive for treating solid tumors, where CAR-T therapy has faced significant challenges.

 

Why TIL Therapy Is Considered Personalized Cancer Immunotherapy

Every patient's tumor possesses unique genetic mutations and antigen profiles.

Because TIL therapy uses immune cells obtained directly from an individual's own tumor, the treatment is inherently personalized.

The transferred lymphocytes are already trained to recognize that patient's specific cancer, reducing the need for artificial receptor engineering and increasing the potential for broader tumor recognition.

As precision oncology continues to evolve, researchers believe TIL therapy will become an increasingly important component of individualized cancer treatment strategies, particularly when combined with genomic profiling, biomarker discovery, immune checkpoint inhibitors, and other advanced immunotherapies.

Clinical Applications of Tumor-Infiltrating Lymphocyte (TIL) Therapy Across Different Cancer Types

The success of Tumor-Infiltrating Lymphocyte (TIL) Therapy has significantly expanded the scope of personalized cancer immunotherapy. Initially developed for advanced melanoma, TIL therapy is now being investigated for a wide range of solid tumors that have historically been difficult to treat with conventional therapies. Its ability to utilize a patient's own tumor-reactive immune cells makes it one of the most promising adoptive cell therapies in precision oncology.

Numerous clinical trials worldwide are evaluating TIL therapy as both a standalone treatment and in combination with immune checkpoint inhibitors, targeted therapies, chemotherapy, and radiation therapy. Researchers believe these combination approaches may further improve treatment outcomes while overcoming resistance to existing immunotherapies.

 

1. Advanced Melanoma

Metastatic melanoma remains the most successful application of TIL therapy.

Melanoma tumors typically contain a large number of naturally occurring tumor-reactive lymphocytes, making them ideal candidates for TIL expansion. Clinical studies have demonstrated durable responses in patients with advanced melanoma who had previously failed immune checkpoint inhibitors and targeted therapies.

Recent regulatory approvals of TIL-based therapies have established this treatment as an important option for patients with advanced melanoma, marking a major milestone in personalized cancer immunotherapy.

Potential benefits include:

• Durable clinical responses
• Long-term disease control
• Improved overall survival
• Enhanced anti-tumor immunity

 

2. Cervical Cancer

Persistent Human Papillomavirus (HPV) infection creates tumor-specific antigens that can be recognized by TILs.

Researchers have reported encouraging clinical responses in patients with recurrent or metastatic cervical cancer treated with TIL therapy, particularly after failure of standard chemotherapy.

Current research is focused on improving:

• T-cell persistence
• Immune activation
• Combination immunotherapy strategies

 

3. Non-Small Cell Lung Cancer (NSCLC)

Lung cancer remains one of the leading causes of cancer-related mortality worldwide.

Although immune checkpoint inhibitors have improved survival for many patients, a substantial proportion eventually develop treatment resistance.

TIL therapy is being investigated to:

• Enhance anti-tumor immune responses
• Target resistant tumors
• Improve progression-free survival
• Increase response to combination immunotherapy

Researchers are particularly interested in combining TIL therapy with PD-1 and PD-L1 inhibitors.

 

4. Ovarian Cancer

Ovarian cancer often presents at advanced stages and has high recurrence rates following chemotherapy.

Studies have shown that ovarian tumors contain immune cells capable of recognizing tumor-associated antigens.

TIL therapy may help:

• Reduce tumor recurrence
• Improve immune surveillance
• Enhance responses to immunotherapy
• Extend progression-free survival

Several early-phase clinical trials continue to evaluate its therapeutic potential.

 

5. Head and Neck Squamous Cell Carcinoma

Head and neck cancers frequently exhibit immune suppression within the tumor microenvironment.

Researchers believe TIL therapy can restore anti-tumor immunity by expanding naturally occurring tumor-reactive lymphocytes capable of recognizing multiple cancer antigens.

Combination strategies involving checkpoint inhibitors are currently under active investigation.

 

6. Colorectal Cancer

Microsatellite instability-high (MSI-H) colorectal cancers often demonstrate increased immune cell infiltration.

This makes selected colorectal tumors attractive candidates for TIL therapy.

Current studies aim to determine:

• Optimal patient selection
• Biomarkers predicting treatment response
• Combination strategies with immunotherapy
• Long-term clinical benefits

 

7. Breast Cancer

Triple-Negative Breast Cancer (TNBC) has emerged as an important area of TIL research.

These tumors often contain immune cell infiltrates associated with improved prognosis.

Researchers are evaluating whether laboratory-expanded TILs can further strengthen anti-tumor immunity in patients with advanced disease.

Potential applications include:

• Metastatic breast cancer
• Triple-negative breast cancer
• Combination with immune checkpoint inhibitors

 

8. Gastrointestinal Cancers

Several gastrointestinal malignancies, including gastric, esophageal, and pancreatic cancers, possess highly complex tumor microenvironments that suppress immune activity.

TIL therapy aims to overcome these barriers by introducing large numbers of activated tumor-reactive lymphocytes capable of recognizing multiple cancer-specific antigens.

Although research remains in its early stages, preliminary clinical findings are encouraging.

 

9. Gynecological Malignancies

Beyond cervical cancer, researchers are investigating TIL therapy in:

• Endometrial cancer
• Ovarian cancer
• Vulvar cancer

These tumors frequently exhibit immune cell infiltration, making them potential candidates for personalized adoptive cell therapy.

 

Combination Therapy: Expanding the Potential of TIL Therapy

One of the most exciting developments in cancer immunotherapy is combining TIL therapy with other advanced treatment modalities.

Current combination strategies include:

• Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4 inhibitors)
• Targeted Therapy
• Cancer Vaccines
• Radiotherapy
• Chemotherapy
• Oncolytic Virus Therapy
• Bispecific Antibodies
• Personalized Neoantigen Vaccines

These combinations aim to enhance immune activation, improve tumor recognition, and achieve more durable clinical responses than any single therapy alone.

 

Recent Advances in TIL Therapy

Recent technological innovations are accelerating the clinical development of TIL therapy.

Key advances include:

• Improved methods for isolating highly active tumor-reactive lymphocytes.
• Faster and more efficient ex vivo T-cell expansion techniques.
• AI-assisted identification of tumor-reactive immune cells.
• Biomarker-guided patient selection.
• Enhanced cell manufacturing technologies.
• Personalized treatment protocols based on genomic and immune profiling.
• Development of next-generation TIL products with improved persistence and anti-tumor activity.

These advances are expected to make TIL therapy more accessible, effective, and applicable across a broader range of solid tumors in the coming years.

Advantages, Challenges, Limitations, and Future Perspectives of Tumor-Infiltrating Lymphocyte (TIL) Therapy

Tumor-Infiltrating Lymphocyte (TIL) Therapy has emerged as one of the most promising advances in personalized cancer immunotherapy. By utilizing a patient's own tumor-reactive immune cells, TIL therapy offers a highly individualized treatment strategy capable of overcoming many limitations associated with conventional cancer therapies. Although remarkable clinical progress has been achieved, several scientific, technical, and logistical challenges remain before TIL therapy becomes widely available for routine clinical practice.

 

Advantages of Tumor-Infiltrating Lymphocyte (TIL) Therapy

1. Personalized Cancer Treatment

One of the greatest strengths of TIL therapy is its personalized approach.

Unlike conventional therapies, TIL therapy utilizes immune cells collected directly from each patient's own tumor. These lymphocytes are naturally capable of recognizing that individual's cancer, making the treatment highly specific and reducing the risk of immune rejection.

This personalized strategy aligns perfectly with the principles of precision oncology.

 

2. Effective Against Solid Tumors

While CAR-T cell therapy has demonstrated remarkable success in blood cancers, treating solid tumors remains a significant challenge.

TIL therapy offers a major advantage because tumor-infiltrating lymphocytes have already migrated into solid tumors and naturally recognize multiple tumor-specific antigens.

This makes TIL therapy particularly promising for:

• Advanced melanoma
• Cervical cancer
• Lung cancer
• Ovarian cancer
• Head and neck cancers
• Colorectal cancer

 

3. Broad Tumor Recognition

Unlike genetically engineered CAR-T cells that typically recognize a single antigen, TILs naturally recognize multiple tumor-associated antigens simultaneously.

This broad recognition reduces the likelihood of tumor escape through antigen loss and improves the ability to target genetically heterogeneous cancers.

 

4. Long-Term Immune Memory

Expanded TILs may persist in the patient's body for extended periods after treatment.

These immune cells continue monitoring for residual or recurring cancer cells, potentially providing durable anti-tumor immunity and reducing the risk of disease relapse.

 

5. Compatibility with Combination Therapy

TIL therapy can be successfully combined with several modern cancer treatments, including:

• Immune checkpoint inhibitors
• Chemotherapy
• Radiotherapy
• Targeted therapy
• Cancer vaccines
• Oncolytic virus therapy

Combination strategies are expected to improve response rates while overcoming immune resistance.

 

6. Improved Survival Outcomes

Clinical studies have demonstrated encouraging long-term responses in patients with advanced melanoma and other difficult-to-treat cancers.

For patients who have exhausted conventional treatment options, TIL therapy offers a valuable new therapeutic opportunity.

 

Challenges and Limitations

Despite its tremendous potential, TIL therapy still faces several important challenges.

1. Complex Manufacturing Process

Producing TIL therapy is labor-intensive and highly individualized.

The process requires:

• Surgical tumor removal
• Specialized laboratory facilities
• Cell isolation
• Large-scale cell expansion
• Strict quality control
• Personalized manufacturing

This complexity increases production time and treatment costs.

 

2. Limited Availability

Currently, TIL therapy is available only at specialized cancer centers with advanced cell therapy infrastructure.

Expanding manufacturing capacity remains essential before widespread clinical adoption becomes possible.

 

3. Treatment Preparation Takes Time

Growing billions of tumor-reactive lymphocytes typically requires several weeks.

Patients with rapidly progressing cancers may not always be able to wait for the manufacturing process to be completed.

Researchers are developing faster expansion protocols to address this limitation.

 

4. Need for Lymphodepleting Chemotherapy

Before receiving TIL infusion, patients usually undergo lymphodepleting chemotherapy.

Although this improves TIL effectiveness, it may temporarily suppress normal immunity and increase the risk of infections or treatment-related side effects.

 

5. High-Dose IL-2 Toxicity

Following TIL infusion, patients often receive high-dose Interleukin-2 (IL-2) to support T-cell expansion.

IL-2 treatment may produce adverse effects including:

• Fever
• Low blood pressure
• Fatigue
• Fluid retention
• Organ-related complications

Researchers are investigating safer alternatives that maintain therapeutic effectiveness while reducing toxicity.

 

6. Variable Patient Response

Not every patient's tumor contains sufficient numbers of highly active tumor-reactive lymphocytes.

In some cases, expanded TILs may demonstrate limited persistence or reduced anti-tumor activity, leading to variable clinical outcomes.

Identifying predictive biomarkers remains an important area of ongoing research.

 

Future Perspectives of TIL Therapy

Rapid advances in immunology, genomics, biotechnology, and artificial intelligence are expected to significantly enhance the future of TIL therapy.

Artificial Intelligence for Patient Selection

Artificial intelligence is being used to:

• Identify patients most likely to benefit from TIL therapy.
• Predict treatment response.
• Analyze tumor immune profiles.
• Optimize personalized treatment strategies.

AI-driven precision medicine is expected to improve clinical success rates.

 

Genomic and Biomarker Integration

Next-generation sequencing and biomarker discovery will help identify:

• Tumor-specific antigens
• Immune signatures
• Predictive biomarkers
• Treatment resistance mechanisms

These molecular insights will allow clinicians to further personalize TIL therapy.

 

Improved Cell Manufacturing Technologies

Researchers are developing automated manufacturing platforms capable of:

• Faster TIL expansion
• Higher cell quality
• Reduced production costs
• Improved accessibility worldwide

Automation may significantly shorten treatment timelines in the future.

 

Combination Precision Immunotherapy

Future treatment strategies are expected to combine TIL therapy with:

• Immune checkpoint inhibitors
• Personalized neoantigen vaccines
• Bispecific antibodies
• Oncolytic virus therapy
• Cytokine engineering
• Targeted therapies

These combinations aim to maximize anti-tumor immunity and improve long-term survival.

 

Expanding Applications Beyond Melanoma

Although melanoma currently represents the most successful indication, ongoing clinical trials are evaluating TIL therapy for:

• Lung cancer
• Breast cancer
• Ovarian cancer
• Colorectal cancer
• Pancreatic cancer
• Gastric cancer
• Liver cancer
• Rare solid tumors

As clinical evidence continues to grow, TIL therapy may become an important treatment option for many additional cancer types.

 

The Future of Personalized Cancer Immunotherapy

Tumor-Infiltrating Lymphocyte (TIL) Therapy represents a major milestone in the evolution of personalized cancer treatment. By utilizing each patient's own tumor-reactive immune cells, TIL therapy offers a highly individualized approach capable of overcoming many limitations associated with traditional therapies. Continued advances in precision oncology, artificial intelligence, biomarker discovery, genomic profiling, and cell engineering are expected to further improve the safety, accessibility, and effectiveness of TIL therapy. As research progresses, this innovative adoptive cell therapy has the potential to become a cornerstone of next-generation cancer immunotherapy, providing new hope for patients with advanced and treatment-resistant solid tumors.

Conclusion

Tumor-Infiltrating Lymphocyte (TIL) Therapy represents a major breakthrough in personalized cancer immunotherapy, offering new hope for patients with advanced solid tumors that have limited treatment options. By harnessing a patient's own tumor-reactive immune cells, TIL therapy provides a highly individualized treatment approach capable of recognizing and eliminating cancer cells while strengthening the body's natural immune response. Unlike traditional therapies and even other forms of adoptive cell therapy, TIL therapy leverages naturally occurring lymphocytes that have already demonstrated the ability to infiltrate tumors, making it a promising strategy for overcoming immune resistance in solid cancers.

Recent clinical advances, including regulatory approvals and encouraging trial outcomes, have highlighted the growing potential of TIL therapy in treating melanoma, cervical cancer, lung cancer, ovarian cancer, and several other solid malignancies. As innovations in artificial intelligence, genomic profiling, biomarker discovery, and cell manufacturing continue to evolve, TIL therapy is expected to become safer, more effective, and accessible to a broader range of cancer patients.

Although challenges such as manufacturing complexity, treatment costs, patient selection, and large-scale clinical implementation remain, ongoing research continues to improve this revolutionary therapeutic approach. Future combination strategies involving immune checkpoint inhibitors, cancer vaccines, targeted therapies, and precision oncology technologies are expected to further enhance treatment outcomes and transform the future of personalized cancer care.

Join leading oncologists, cancer researchers, clinicians, immunologists, and healthcare professionals at the International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027), taking place March 25–27, 2027, in Osaka, Japan, to explore the latest breakthroughs in Tumor-Infiltrating Lymphocyte (TIL) Therapy, precision oncology, cancer immunotherapy, cellular therapies, artificial intelligence, molecular diagnostics, and next-generation cancer treatments.

🌐 Conference Website: https://www.cancer.theiconicmeetings.com/

Become part of a global scientific community dedicated to advancing personalized cancer treatment through collaboration, innovation, and cutting-edge oncology research.

 

Frequently Asked Questions (FAQs)

1. What is Tumor-Infiltrating Lymphocyte (TIL) Therapy?

TIL Therapy is a personalized form of adoptive cell therapy that uses a patient's own tumor-reactive immune cells to recognize and destroy cancer cells.

2. How does TIL Therapy differ from CAR-T Cell Therapy?

Unlike CAR-T therapy, TIL therapy uses naturally occurring lymphocytes isolated from a patient's tumor without genetic modification, making it particularly effective for treating solid tumors.

3. Which cancers can be treated with TIL Therapy?

TIL Therapy is currently being investigated for melanoma, cervical cancer, lung cancer, ovarian cancer, colorectal cancer, head and neck cancers, and several other solid tumors.

4. Is TIL Therapy FDA-approved?

Yes. Certain TIL-based therapies have received regulatory approval for advanced melanoma, while many additional clinical trials are evaluating their use in other cancers.

5. Why is TIL Therapy considered personalized medicine?

Because the immune cells used in treatment are collected directly from the patient's own tumor, making the therapy uniquely tailored to each individual.

6. What are the major advantages of TIL Therapy?

It offers personalized treatment, broad tumor recognition, durable immune responses, effectiveness against solid tumors, and compatibility with combination immunotherapies.

7. What are the limitations of TIL Therapy?

Challenges include complex manufacturing, high treatment costs, lengthy cell expansion, limited availability, and the need for specialized treatment centers.

8. Can TIL Therapy be combined with other cancer treatments?

Yes. Researchers are evaluating combinations with immune checkpoint inhibitors, chemotherapy, radiotherapy, cancer vaccines, targeted therapy, and oncolytic virus therapy.

9. What role does artificial intelligence play in TIL Therapy?

AI helps identify suitable patients, predict treatment responses, analyze tumor immune profiles, and optimize personalized treatment strategies.

10. Why is TIL Therapy important for the future of oncology?

Its ability to deliver highly personalized, immune-based treatment for solid tumors makes it one of the most promising next-generation cancer immunotherapies.

 

References

• National Cancer Institute (NCI)
• American Society of Clinical Oncology (ASCO)
• American Association for Cancer Research (AACR)
• European Society for Medical Oncology (ESMO)
• Nature Reviews Cancer
• Nature Medicine
• The New England Journal of Medicine (NEJM)
• The Lancet Oncology
• Clinical Cancer Research
• Cancer Discovery

 

Related Articles

• Oncolytic Virus Therapy: Harnessing Engineered Viruses to Revolutionize Precision Cancer Treatment
• Multi-Omics Integration in Precision Oncology: Combining Genomics, Transcriptomics, Proteomics, and Metabolomics
• Synthetic Lethality in Cancer Therapy: Revolutionizing Precision Oncology Through Targeted Genetic Vulnerabilities
• Ferroptosis in Cancer: A Novel Cell Death Pathway Transforming Future Cancer Therapy
• Digital Twins in Oncology: The Future of Personalized Cancer Treatment and Clinical Decision-Making
• Proteogenomics in Oncology: Bridging Genomics and Proteomics for Next-Generation Precision Cancer Care
• Minimal Residual Disease (MRD): Transforming Precision Oncology Through Ultra-Sensitive Cancer Monitoring
• Bispecific Antibodies in Cancer Therapy: The Next Frontier of Precision Immuno-Oncology